 |
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Reducing Infections Reduces Costs How will an uncoated, unprotected catheter help? It stands to reason then that institutions wanting to cut costs should focus on cutting their rate of infection. And that’s exactly what our ARROWg+ard® technology can do. See How Much You Can Save With ARROWg+ard See how much you can save by using our online savings calculator. Enter the following information:
Proven Defense Against Infection Pioneers in infection prevention Over 30 clinical reviews validate the effectiveness, safety and cost benefit of using our innovative ARROWg+ard antiseptic technology. No other company’s catheters have such a strong track record. We pioneered the antiseptic-impregnated catheter in 1990. Since then our innovative ARROWg+ard antiseptic technology has been proven to reduce catheter-related bacteremia by 80 percent.2 Now our latest breakthrough, ARROWg+ard Blue PLUS®, gives you that proven infection-fighting ability both outside and in, including extension lines and hubs. So chlorhexidine and silver sulfadiazine continuously prep the subcutaneous catheter tract and kill organisms in places that you simply can’t reach. "CDC Guidelines for the Prevention of Intravascular Catheter-Related Infections" specifically recommend using a chlorhexidine-silver sulfadiazine-impregnated catheter in conjunction with other risk-reduction measures to lower incidence of CRBSI--and caution that antibiotic-coated catheters could increase the incidence of resistant pathogens.3 References 1O’Grady et al. “Guidelines for the Prevention of Intravascular Catheter-Related Infections,” Infection Control Hospital Epidemiology, Dec. 2002, Vol. 23, Issue 12, pp. 759–769. 2Maki, D.G., Stolz, S.M., Wheeler, S., Mermel, L.A. “Prevention of Central Venous Catheter-Related Bloodstream Infection With an Antiseptic-Impregnated Catheter: A Randomized, Controlled Trial,” Annals of Internal Medicine, August 15, 1997, Vol. 127, Issue 4, pp. 257–266. 3O'Grady, N.P., Alexander, M., Dellinger, E.P., Gerberding, J.L., Heard, S.O.Maki, D.G., Masur, H., McCormick, R.D., Mermel, L.A., Pearson, M.L., Raad, I.I., Randolph, A., Weinstein, R.A. “Guidelines for the Prevention of Intravascular Catheter-Related Infections,” The Centers For Disease Control, August 9, 2002, Vol. 51, No. RR10, pp. 7–8. Full bibliography available upon request. Patents ARROWg+ard/ARROWg+ard Blue PLUS: U.S. Patent Nos. 5,019,096, Sample calculation of savings using ARROWg+ard-impregnated catheter
For more information please call Arrow Customer Service.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Catheter-related bloodstream infections (CRBSIs) do happen. Even highly focused programs in hospitals report low CRBSI rates between 2 and 5 percent. But no matter how infrequent they may be, CRBSIs are expensive. Treating a single incident can total $56,000 or more due to pharmacy charges, catheter changes, additional days in the ICU, lab tests and extended hospital stays.1